Unaudited Financial Results along with Limited Review Report as submitted by the Statutory Auditor of the Company for the Third Quater and Nine Months Ended 31st December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.2 pts less than Nifty Microcap 250 and 3.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanjivani Paranteral Ltd reported strong Q3 FY26 results with standalone revenue from operations rising ~20.2% YoY to Rs. 2,086.32 lacs (vs Rs. 1,734.91 lacs in Q3 FY25). Net profit jumped ~37.8% YoY to Rs. 261.67 lacs. For nine months, revenue grew ~4.5% to Rs. 5,425.27 lacs while net profit was largely flat at Rs. 598.58 lacs (vs Rs. 590.82 lacs). Consolidated figures were even stronger, with Q3 revenue at Rs. 2,206.29 lacs and net profit at Rs. 277.63 lacs. However, EPS for 9M slipped slightly to Rs. 4.87 from Rs. 5.06 due to dilution from warrant-to-equity conversion. Cost of materials rose sharply (~48% YoY for 9M), though overall profitability held up. Statutory auditor R.B. Gohil & Co. issued an unqualified limited review report with no qualifications or emphasis of matter.
Strong quarter-on-quarter momentum with both revenue and profit growth, expanding margins, and new IV fluid plant contributing — likely positive for the stock. Watch for rising raw material costs and EPS dilution from share issuance.